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ABSTRACT 
Objective: Considering the interest in L. nuda as a source of ingredients for the development of functional food and nutraceuticals has increased, the 
objective of this study was to evaluate its general toxicity and possible genotoxic effects in rats to assess its safety.  
Methods: This study evaluated the safety of L. nuda mycelium by using genotoxicity assays (reverse mutation, chromosomal aberration, and 
micronuclei tests) and a short-term toxicity test.  
Results: Our results have indicated that L. nuda mycelium did not significantly increase the number of revertant colonies and chromosomal 
aberration in both in vitro assays. Furthermore, it did not induce any increase in micronuclei formation in mouse bone marrow.  
Conclusion: In summary, no mutagenic effects and no evidence of systemic toxicity were found in this safety assessment, and the use of L. nuda 
mycelia is safe at a dose of 3 g/kg body weight in S-D rats. Using a safety factor of 100, the calculated acceptable daily intake in humans is 30 mg/kg 
body weight/d.  
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INTRODUCTION 
Mushrooms have been a part of regular diets for their nutritional 
and medicinal values since ancient times. They are low in fat content 
and high in minerals, vitamins, fibers, proteins and polysaccharides 
[1]. Recently, there has been an increased consumption of 
mushrooms due to a significant number of studies conducted that 
focused on isolating and identifying compounds with promising 
therapeutic properties from various species of fungi [2]. These 
mushrooms possess bioactive compounds such as phenolics, 
tocopherols, ascorbic acid, carotenoids and ergothioneine (EGT) 
[3]which are identified as ingredients for the development of 
functional foods or medicinal products. Moreover, such bioactive 
substances are not only available in the form of fruiting bodies, but 
also as mycelial biomass that may be beneficial for human health [4]. 
Lepista nuda (Bull. ex Fr.) Cooke (Tricholomataceae) is an edible 
woodland mushroom that grows in Asia, Africa, America, Australia and 
Europe [5]. It is valued internationally for its lilac color, delicate flavor, 
special aroma and good post harvest conservation, all of which lead to 
its consumption and even its cultivation [6]. Recent studies indicate 
that L. nuda has a wide range of pharmacological functions, including 
anti-tumor [7], immune-modulatory [8], anti-oxidant [9], anti-
microbial [10], anti-diabetic and anti-hyperlipidemic [11] properties. 
The fruiting body of L. nuda contains a number of secondary 
metabolites, including sterols, triterpenoids [12], ceramides [13] and 
EGT [14], which are known to possess various beneficial health effects. 
In general, the production of a fruiting body is a time-consuming and 
labor-intensive process. From an ecological point of view, utilizing in 
vitro culture minimizes the overexploitation of endangered, rare or 
valuable species, representing a promissory methodology that 
prioritizes sustainable conservation and rational use of biodiversity. 
The use of submerged cultivation of edible and medicinal 
mushrooms has started to attract attention around the world and is 
viewed as a promising alternative for the production of important 
metabolites [15-17]. Therefore, it seems highly desirable to produce 
L. nuda via submerged fermentation in a batch stirred tank 
bioreactor with controlled culture parameters for faster production 
of mycelia biomass and metabolites, which would be useful for 
further development on an industrial scale. 
Considering the interest in L. nuda as a source of ingredients for the 
development of functional food and nutraceuticals has increased, the 
objective of this study was to evaluate its general toxicity and possible 
genotoxic effects in rats to assess its safety. To the best of our knowledge, 
there have been no toxicological or genotoxicological studies on the 
safety of L. nuda mycelium. Hence, this study will evaluate the safety of L. 
nuda in subchronic studies and genotoxicity assays. 
MATERIALS AND METHODS 
Sample preparation 
L. nuda strain NO. 8620 purchased from German Collections of 
Microorganisms and Cell Cultures (DSMZ) biological resource center 
(Braunschweig, Germany) was cultured on potato dextrose agar at 
24 °C for 14 d. The agar block (1 cm3) containing mycelia was then 
transferred to a 2-L Erlenmeyer flask with 1l broth (composed of 
soybean powder, glucose, maltose syrup, peptone, yeast extract, 
MgSO4 and KH2PO4
14
, adjusted to pH 4.5 with 1N HCl) and was 
cultured at 24 °C for 12 don a rotary shaker (120 rpm) for seed 
culturing prior to its scale-up production step. The scale-up of the 
fermentation process was performed using the same media in the 
200-L fermenter agitated at 60 rpm with an aeration rate of 0.375 
vvm at 24 °C for 14 d. At the end of the cultivation, L. nuda mycelia 
were lyophilized, reduced to a fine dried powder using a 60 mesh 
and stored in a desiccator at room temperature. The dry sample was 
then analyzed by high performance liquid chromatography (HPLC) to 
evaluate the active EGT content in the mycelia based on its dry weight. 
HPLC analysis of EGT was executed according to the previous study [ ], 
and the retention time of EGT was approximately ~9 min at a flow rate 
of 1.0 ml/min with a scanning UV wavelength at 254 nm. Proximate 
analysis and heavy metals determination were carried out using the 
standard procedures [18]. 
Animals and husbandry 
Seven-week-old male and female ICR mice and Sprague-Dawley (S-
D) rats were purchased from Bio LASCO Taiwan Co., Ltd (I-Lan, 
Taiwan). The studies were conducted in compliance with Good 
Laboratory Practice (21 CFR Part 58), conformed to the guidelines 
set forth by the National Institutes of Health (NIH) for the care and 
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use of laboratory animals and approved by the Institutional Animal 
Care and Use Committee (Approval no. 130110-13 and 130111-12 
for in vivo erythrocyte micronucleus, acute and subchronic tests, 
respectively). Animals were kept in polypropylene cages under an 
ambient temperature of 21±2 °C and 55±20 % relative humidity with 
a 12 h light/dark cycle throughout the test period. Water and food 
(Rodent Lab Diet 5010; PMI®
The protocol was conducted according to Organization for Economic 
Cooperation and Development (OECD) Test No. 471[
 Nutrition International, LLC, Indiana, 
USA) was available ad libitum. All animals had their health status 
evaluated, quarantined and acclimatized for a week before any test. 
Ames test (bacterial reverse mutation test) 
19]: Bacterial 
reverse mutation test. Five Salmonella typhimurium strains of 
histidine auxotrophs TA98, TA100, TA102, TA1535 and TA1537 
(MoltoxInc, USA), were used to evaluate the genotoxic potential of L. 
nuda mycelium in the presence and absence of S9 metabolic 
activation [20]. 0.05 ml of each testing sample (L. nuda powder, 
positive control, and negative control separately), 2 ml top agar 
containing 0.5 mM histidine/biotin solution, and 0.1 ml bacterial 
culture liquid (37±1 °C cultured overnight) were mixed thoroughly 
with and without S9 activation and then poured onto the surface of 
minimal glucose agar plates. Afterwards, the plates were incubated 
invertedly at 37±1 °C in the dark for 48-72 h prior to revertant 
colonies counting. 
In vitro chromosome aberration test 
The test was performed according to OECD Guideline Test No. 473 
[21]: In vitro mammalian chromosome aberration test. Chinese 
hamster ovary cells (CHO-K1; BCRC 60006) seeded at a density of 3-
4×105
This test protocol is based on OECD Guideline Test No. 474 [
 cells/well in 6 cm dishes were exposed to dimethyl sulfoxide, 
positive controls (mitomycin C (0.5 μg/ml) and  benzo (a) pyrene 
(25 μg/ml))or L. nuda mycelium (1.25, 2.5 or 5 mg/ml) for 3 -24 h, 
with and without S9-mix metabolic activation. At the end of the 
treatment, cells were treated with 0.1 μg/ml demecolcine solution 
(Sigma-Aldrich, MO, USA), swelled by 0.075 M KCl and fixed with 
methanol/acetic acid solution (3:1, v/v). The cells were then spread 
on glass slides and stained with Giemsa. Structural chromosome 
aberration such as chromosome-type break (csb), chromosome-type 
exchange (cse), chromatid-type breakage (ctb) and chromatid-type 
exchange (cte) were observed and recorded.  
In vivo erythrocyte micronucleus test 
22]: 
Mammalian erythrocyte micronucleus test. Each testing group 
(positive control, negative control, low, mid and high dose group) 
contained five females and five male ICR mice. Negative controls 
were administrated with sterilized water, and positive controls were 
given an intraperitoneal injection of 8 ml/kg body weight 
cyclophosphamide monohydrate. The low, mid and high dose groups 
were orally treated with a single dose of L. nuda mycelium at 1250, 
2500 and 5000 mg/kg, respectively. Peripheral blood (2-3 ml) was 
collected from the tail vein at 48 h and 72 h after dosing, which was 
then applied to acridine orange-coated slides in the dark for 2~3 h 
under room temperature and was examined using a fluorescent 
microscope. The percentage of polychromatic erythrocytes (PCEs) in 
1000 erythrocytes and the incident of micro nucleated 
polychromatic erythrocytes (MNPCEs) in 2000 PCEs were calculated 
for each animal collected at 24 and 72 h time points. 
4-w subchronic toxicity test 
This test was conducted in accordance to OECD Guideline Test No. 
407 [23]: Repeated dose 28-d oral toxicity study in rodents. Eighty 
healthy adult S - Drats were randomly divided into four groups 
according to their body weight (10 males and 10 females per group). 
Our earlier study on acute oral toxicity indicated that acute oral LD50
All values in this study were presented as mean±standard deviation 
(SD). Poisson distribution was used for the statistical evaluation of 
the number of cells in the chromosome aberration test and the 
frequency of micronucleus in the erythrocyte micronucleus test. 
Values were compared with the control group by Dunnett’s t-test in 
Ames and 4-w subchronic toxicity tests. In the chromosome 
aberration test and micronucleus test, the Cochran-Armitage trend 
test (C-A test) was conducted in order to identify any dose-response 
that may be significantly different between the testing group and the 
negative control group. A P value less than 0.05 was considered 
statistically significant. 
RESULTS AND DISCUSSION 
 
of L. nuda was greater than 12 g/kg in S-D rats (data not shown). 
Hence, the following three doses were selected for the study: 1 
g/kg/d (Low dose), 2 g/kg/d (Mid dose) and 3 g/kg/d (High dose). 
Distilled water was served as the control. Body weight, food 
consumption, and water intake (the difference between the food 
given and their remnants the next day) was recorded weekly. 
Mortality and morbidity were observed twice a day. At the end of the 
stipulated experiment, all overnight fasted rats (with water still 
supplied ad libitum) were sacrificed and the toxicological and 
histopathological changes were evaluated. 
Toxicological evaluation 
Urine and blood samples were collected from the rats before they 
were sacrificed. The 12 to 16 h urine specimens were collected using 
metabolic cages and were evaluated by using urinalysis equipment 
(Bayer Clinitek-Status, Siemens, USA) for the following parameters: 
pH, specific gravity, protein, glucose, ketone, bilirubin, urobilinogen, 
occulted blood, leukocytes and nitrite. Urinary sediments 
examination was further evaluated by using a microscopic 
equipment (Model-E200, Nikon, Japan) to observe the presence of 
red blood cells, white blood cells, epithelial cells, casts, crystals and 
microbes. The blood samples were collected via the abdominal 
aortic method and were transferred into non-anticoagulated-
containing tubes for serum biochemistry analysis and sodium 
citrate-containing tubes for haematological analysis. Serum 
biochemistry and haematological profiles were obtained using a 
biochemistry analysis equipment (Model-7080, Hitachi, Japan) and 
haematology analyzers (Sysmex Xt-1800i and Sysmex CA-500, 
Sysmex Corporation, Japan), respectively. For the serum 
biochemistry analysis, amylase, albumin, alkaline phosphatase 
(ALP), total bilirubin (T-BIL), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), gamma-glutamyl-transferase (γ-
GT), total protein (TP), creatinine (CRE), blood urea nitrogen (BUN), 
cholesterol (CHO), triglycerides (TG), creatine kinase (CK), chloride 
(Cl), sodium (Na), potassium (K), glucose (GLU), calcium (Ca) and 
phosphorus (P) were examined. The haematological parameters 
including red blood cell (RBC), white blood cell (WBC), platelet, 
haemoglobin (HGB), haematocrit (HCT), mean corpuscular volume 
(MCV), mean corpuscular haemoglobin (MCH), mean corpuscular 
haemoglobin concentration (MCHC), neutrophils, eosinophils, 
basophils, monocytes, lymphocytes, activated partial thrombo 
plastin time (APTT) and prothrombin time (PT) were measured. 
Pathology and histopathology 
Gross necropsies were performed in order to analyze the external 
and internal surfaces of the body. Organs such as heart, liver, spleen, 
kidney (paired), adrenal gland (paired), thymus, epididymis 
(paired), testes (paired), ovary (paired), and uterus were weighted 
and then fixed in 10 % formalin neutral buffer. The tissues obtained 
from these fixed organs were then stained with haematoxylin-eosin 
(H&E) and were viewed using optical microscope (Model-E200, 
Nikon, Japan).  
Statistical analysis 
L. nude has been widely consumed for a long period of time, 
especially in Europe. They are valued as highly flavorsome foods and 
are also considered as a rich source of bioactive compounds such as 
EGT. Despite its widespread use, no scientific studies have been 
undertaken to determine its toxicity. The nutrient contents of the 
mushrooms are influenced by many factors, such as the types of 
substrate on which they were cultivated [24]. For this reason, 
submerged fermentation proved to be a promising and reproducible 
alternative as it avoids the overexploitation of endangered, rare or 
valuable species, and offers advantages of efficient production of 
mushroom mycelium and metabolites in a faster and more easily 
controlled process [25]. Since the chemical composition, nutritional 
values and medicinal values of fruiting bodies may differ between 
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the natural environment and submerged cultured mycelia, the safe 
dose range of this mushroom obtained from submerged 
fermentation should be analyzed. Hence, this is the first report on 
the evaluation of the toxicity of submerged cultured L. nuda 
mycelium, which was conducted in parallel with the OECD 
guidelines to assess its safety as a source for the development of 
medicines, nutraceuticals or functional foods. 
The proximate composition of freeze-dried L. nuda mycelia is shown 
in table 1. L. nuda mycelium was composed of 11.85 % moisture, 
4.65 % ash, 32.8 % crude protein, 9.65 % crude fat and 41.05 % 
carbohydrate, which were completely distinct from the values of the 
fruiting body reported earlier [5] (93.77 %, 1.15%, 3.70%, 0.11 % 
and 1.55 %, respectively). The moisture content of the mycelia 
exhibited lower values than the fruiting body.  
This finding supports previous research indicating that fresh fruiting 
bodies contained about 90 % moisture and 10 % dry matter, and 
dried mushrooms contained approximately 90 % dry matter and 10 
% moisture [26]. The greater ash content showed that L. nuda 
mycelium is higher in mineral content. Furthermore, the relatively 
higher contents of protein, carbohydrate, and low fat in L. nuda 
mycelium provide a proof of it being a better candidate than the 
fruiting body as an ideal functional food for human consumption. 
 
Table 1: Proximate analysis (g/100g) of freeze-dried L. nuda mycelium 
Proximate composition Freeze-dried L. nuda 
Moisture 11.85 ± 5.73  
Ash 4.65 ± 0.78  
Crude Protein 32.80 ± 3.96  
Crude Fat 9.65 ± 2.47  
Carbohydrate 41.05 ± 7.99  
Energy 382 ± 38  
Average±SD, n=2    
 
EGT has been known as an excellent antioxidant that has a 
protective effect on the organs of rats against lipid peroxidation 
[27]. Unfortunately, this unique naturally occurring potent antioxidant 
cannot be made in human cells and therefore is only available from 
diet through a specific ergothioneine transporter [28]. Moreover, food 
processing tends to destroy many active compounds [29], but in this 
study, a proportion of the EGT remained. 60 ppm EGT in L. nuda 
mycelium was confirmed and quantified by HPLC as shown in fig. 1. 
This suggests that there is a potential in developing ergothioneine-rich 
L. nuda mycelium nutritional supplement as an ingredient in 
functional foods or medicinal products intended to prevent and treat 
chronic inflammatory diseases. 
 
Fig. 1: HPLC chromatograms of standard EGT sample (top; 50 
ppm EGT) and extracted L. nuda mycelium (bottom; 60 ppm 
EGT) from 200-L bioreactor (UV detection at 254 nm). 
Retention time of EGT is 8.9 min 
 
When a functional food contains novel ingredients, its safety for 
consumption as well as its acceptability becomes particularly 
important to investigate. Earlier studies have raised concerns about 
possible contamination of L. nuda fruiting bodies with heavy metals 
such as arsenic, lead, cadmium and mercury [30]. In this study, L. 
nuda mycelia were analyzed for the presence of arsenic, lead, 
cadmium and mercury. The mean values and range of heavy metals 
were all within the daily intake levels (data not shown). The overall 
result from proximate and metal analyses showed L. nuda mycelia 
being a more suitable candidate than its fruiting bodies as an 
excellent food for good health. 
In vitro methods with high throughput screening capacity and good 
predictability such as the Ames test, the chromosomal aberration 
test and the micronucleus test have a high false-positive rate for 
predicting in vivo genotoxicity and carcinogenicity [31]. Hence, the 
bacterial reverse mutation test, chromosome aberration test and 
micronucleus test were conducted to evaluate the safety of L. nuda 
mycelia consumption for the general public. Ames test has been used 
worldwide for the geno toxicity of a compound [32]. In our study, all 
S. typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 
exposed to different concentrations of L. nuda mycelia with the 
presence and absence of S9-Mix metabolic activators did not show a 
two-fold increase in revertant numbers over the negative control 
(table 2). The validity of the assay was observed by the marked 
increase in the number of revertant colonies in the positive control 
(P<0.05). These results of Ames test indicated that L. nuda mycelia 
displayed no mutagenicity. 
Similarly, in vitro chromosomal aberration test did not show any 
significant alterations up to a dose of 5 mg/culture when compared 
to the negative control in the presence and absence of S9-Mixture 
(table 3). The validity of the assay is supported as the negative 
controls induced less than 3 % of cells with chromosomal 
aberrations, and positive controls induced a significant increase of 
aberrations (P<0.05). The number of cells with chromosome 
aberration recorded in 200 metaphase cells under 3 h treatment in 
the absence of metabolic activation was 5, 2, and 1 at 5, 2.5 and 1.25 
mg per culture respectively, with 6 in vehicle control group and 22 
in the positive control group. Likewise, longer treatment or 
metabolic activation of L. nuda mycelia did not interfere with the 
mitotic process or cell cycle progression. In summary, L. nuda 
mycelia up to 5 mg/ml were found to be non-clastogenic to CHO-K1 
cell line in both the presence and absence of metabolic activation. 
L. nuda mycelia were further investigated by using the in vivo 
erythrocyte micronucleus test in ICR mice to test whether it resulted 
in chromosomal damage. The results of ICR mice bone marrow 
erythrocyte micronucleus assay are shown in Tables 4 and 5. A 
reduced ratio of polychromatic erythrocytes to total erythrocytes 
and an increased frequency of micro nuleated polychromatic 
erythrocytes were found in the positive control group treated with 
cyclophosphamide (P<0.05). The proportion of PCEs and the 
incidence of MNPCEs in L. nuda mycelia treatment groups (1.25, 2.5 
and 5 g/kg body weight) were not significantly different from the 
negative control groups (P>0.05). These results were thus consistent 
with those of the in vitro mutagenicity test, providing that L. nuda 
mycelia are not mutagenic at the tested dosage range. 
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Table 2: Bacterial reverse mutation test of L. nuda mycelia using Salmonella typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 
Dose (mg/plate) Number of revertants/plate (without S9 activation) 
TA98 TA100 TA102 TA1535 TA1537 
Negative Control 54.3 a ± 10.3 181.7 ± 9.1 306.7 ± 17.0 9.7 ± 4.0 12.0 ± 2.6 
Positive Control 197.7 b ± 25.2 729.3 * ± 89.7 3392.0 * ± 334.1 426.7 * ± 26.3 251.0 * ± 26.8
0.625 
* 
38.0 ± 5.0 196.3 ± 8.0 291.3 ± 17.2 16.3 ± 2.9 15.0 ± 5.3 
0.313 35.7 ± 4.0 183.7 ± 8.4 297.3 ± 24.2 17.3 ± 4.0 12.0 ± 2.0 
0.156 34.7 ± 4.2 189.0 ± 9.5 287.3 ± 14.6 9.7 ± 0.6 10.7 ± 2.9 
0.078 31.3 ± 3.5 188.3 ± 13.4 309.7 ± 11.0 12.0 ± 3.6 13.0 ± 3.0 
0.039 37.0 ± 5.2 181.0 ± 16.5 299.7 ± 7.5 10.7 ± 3.1 14.0 ± 1.7 
 Number of revertants/plate (with S9 activation) 
  TA98 TA100 TA102 TA1535 TA1537 
Negative Control 36.3 a ± 8.4 182.3 ± 8.4 321.7 ± 9.6 12.0 ± 2.6 11.3 ± 4.5 
Positive Control 918.3 c ± 126.1 833.3 * ± 30.0 956.7 * ± 88.2 264.5 * ± 6.4 601.7 * ± 82.0
0.625 
* 
51.0 ± 2.6 186.3 ± 3.1 390.7 ± 11.2 20.4 ± 2.6 14.7 ± 4.2 
0.313 45.0 ± 1.0 186.0 ± 3.5 391.3 ± 20.4 16.3 ± 3.8 11.0 ± 2.6 
0.156 43.0 ± 6.2 191.0 ± 8.9 405.7 ± 9.0 15.3 ± 5.7 12.7 ± 3.1 
0.078 41.3 ± 2.5 181.7 ± 13.4 383.7 ± 17.9 14.7 ± 1.5 10.3 ± 3.2 
0.039 41.0 ± 1.0 180.3 ± 7.4 384.0 ± 6.6 14.7 ± 0.6 11.3 ± 3.1 
Data were expressed as mean±SD (n=3), aSterilized water, bTA98: 2-nitrofluorene, 1μg/plate; TA100: Sodium azide, 1μg/plate; TA102: Mitomycin C, 
0.2μg/plate; TA1535: Sodium azide, 1μg/plate; TA1537: 9-aminoacridine, 50 μg/plate, cTA98: 2-aminoanthracene, 1μg/plate; TA100: 
Benzo[a]pyrene, 1μg/plate; TA102: 2-aminoanthracene, 5μg/plate; TA1535: 2-aminoanthracene, 5μg/plate; TA1537: 2-aminoanthracene, 5 
μg/plate, *
Dose 
A two-fold or greater increase in revertant numbers over the negative control. 
 
Table 3: Chromosome aberration test of L. nuda mycelia using CHO-K1 cells 
S9-Mixture ctb cte csb cse other AF Total number of aberrations d 
3 h treatment 
Negative control - a 5 0 0 1 0 5/200 6 
Positive control - b 13 5 3 1 0 21/200* 22 
5 mg/ml - 3 1 1 0 0 5/200 5 
2.5 mg/ml - 1 0 1 0 0 2/200 2 
1.25 mg/ml - 0 0 0 0 1 1/200 1 
Negative control + a 4 0 0 0 0 1/200 4 
Positive control + c 12 8 1 2 1 23/200* 24 
5 mg/ml + 3 1 0 0 0 4/200 4 
2.5 mg/ml + 2 0 0 0 0 2/200 2 
1.25 mg/ml + 1 0 0 1 1 3/200 3 
18h treatment 
Negative control - a 1 0 1 0 0 2/200 2 
5 mg/ml - 5 0 0 0 0 5/200 5 
2.5 mg/ml - 2 0 0 1 0 3/200 3 
1.25 mg/ml - 0 0 1 0 0 1/200 1 
aCulture medium. bMitomycinC (0.5 μg/ml)., cBenzo(a)pyrene (25 μg/ml)., d
Dose (mg/kg) 
Aberration frequency (AF): Number of cells with chromosome 
aberration in 200 metaphase cells (n/200). ctb: chromatid breakage; cte: chromatid exchange; csb: chromosome breakage; cse: chromosome 
exchange; other: other abnormalities, *Significantly different when compared to the negative control, P<0.05. 
 
Table 4: Percentage of PCEs in erythrocytes of male and female mice at 48 h and 72 h after L. nuda mycelia treatment 
PCE (%) 
 Male Female 
 48 h 72 h 48 h 72 h 
Negative control 3.92 ± 0.27 3.70 ± 0.07 3.80 ± 0.07 3.78 ± 0.04 
Positive control (80 mg/kg) 1.40 ± 0.07 - 1.38 ± 0.24 - 
1.25 3.86 ± 0.21 3.86 ± 0.05 3.94 ± 0.23 3.74 ± 0.05 
2.5 3.92 ± 0.16 3.78 ± 0.08 3.84 ± 0.13 3.78 ± 0.08 
5 3.92 ± 0.19 3.76 ± 0.05 3.88 ± 0.22 3.82 ± 0.08 
Data are expressed as the percentage of polychromatic erythrocytes (PCEs) in 1000 erythrocytes (n=5) 
 
Table 5: Micronucleus frequency in PCEs of male and female mice at 48 h and 72 h after L. nuda mycelia treatment 
Dose (g/kg) MNPCE (%) 
 Male Female 
 48 h 72 h 48 h 72 h 
Negative control 0.50 ± 0.35 0.30 ± 0.27 0.30 ± 0.27 0.40 ± 0.65 
Positive control (80 mg/kg) 13.40 ± 3.49* - 12.10 ± 2.97* - 
1.25 0.40 ± 0.22 0.50 ± 0.35 0.40 ± 0.22 0.40 ± 0.42 
2.5 0.50 ± 0.35 0.50 ± 0.35 0.20 ± 0.27 0.20 ± 0.27 
5 0.40 ± 0.22 0.40 ± 0.55 0.50 ± 0.35 0.50 ± 0.00 
Data are expressed as the incident of micronuleated polychromatic erythrocytes in 2000 PCEs (n=5), *p＜0.05: Significantly different when 
compared to negative control via Poisson distribution. 
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 between 5 and 15g/kg of any substance is 
considered non-toxic [ ]. From our previous study, L. nuda mycelia 
could be characterized as non-toxic because its LD50 was found to be 
greater than 12 g/kg in S-D rats (data not shown). However, this LD50 
 
Fig. 2: Effects of L. nuda mycelia on body weight in male and 
female S-D rats during the 4-w safety assessment. Data were 
expressed as mean±SD (n=10) 
value does not reflect enough information to categorize the toxic 
property of the compound nor does it suggests the mechanism of action 
of the compound. In order to select the appropriate starting dose that is 
safe for human consumption, the information on the degree of toxicity 
after repeated exposure to it over a long period of time is therefore 
required. Regarding the long term effects of L. nuda mycelia in S-D rats, 
no toxicity, morbidity nor mortality was noted in both the male and 
female rats that were given three dosages (1, 2 and 3 g/kg/body weight) 
during the 4-w testing period (n=10). No significant changes were found 
in body weight (P>0.05) (fig. 2) or food consumption (P>0.05) (fig. 3), 
regardless of sex or treatment. All haematology measures (WBC, RBC, 
HGB, HCT, MCV, MCH, MCHC, platelet, neutrophil, lymphocyte, monocyte, 
eosinophil, basophil, PT and APTT) in treated rats revealed no significant 
difference (P>0.05) between the treatment group and the control group 
in both male and female rats (table 6). Serum biochemistry profiles are 
shown in table 7.  
 
Fig. 3: Effects of L. nuda mycelia on food intake in male and 
female S-D rats during the 4-w safety assessment. Data were 
expressed as mean±SD (n=5 cages, two animals per cage) 
 
Most serum biochemistry parameters in treated rats were not 
significantly different from the negative control group, with the 
exception of variations in AST, TP, ALP, P, Na and Cl values of male 
rats and in CK measures of female rats. AST levels were significantly 
decreased (P<0.05) (mid-dose group: 97.97±14.20 U/l) while TP 
(low-dose group: 5.82±0.15 g/dl), ALP (high-dose group: 
668.93±163.19 U/l) and P (high-dose group: 8.48±0.37 mg/dl) 
concentrations were significantly increased (P<0.05) compared to 
the control male rats. However, these parameters were not dose-
dependent and therefore were not considered to be a treatment-
related effect. Additionally, all values were in the range of normal 
values [34]. Significant increases (P<0.05) in serum electrolytes such 
as sodium and chloride were noted in all dosage groups, but these 
values remained within the normal range [35]. Furthermore, female 
rats demonstrated a significant elevation in creatine kinase levels 
(low-dose group: 274.58±153.56 U/l) when compared to control 
animals. However, such alteration was not dose-related and should 
be assumed as toxicologically irrelevant as it was within normal 
physiological ranges [36]. 
Table 6: Effects of L. nuda mycelia on haematological parameters in male and female S-D rats during the 4-w safety assessment 
Parameters Control 
(Distilled water) 
L. nuda mycelia (g/kg/d) 
1 g/kg/d 2 g/kg/d 3 g/kg/d 
Male 
WBC (103 9.030  µl) ± 1.690 8.867 ± 2.587 8.917 ± 1.460 9.553 ± 1.307 
RBC (106 8.028  µl) ± 0.478 7.985 ± 0.308 8.128 ± 0.292 7.921 ± 0.327 
HGB (g/dl) 15.87 ± 0.57 15.66 ± 0.32 15.95 ± 0.34 15.64 ± 0.53 
HCT (%) 44.09 ± 1.60 43.37 ± 0.89 44.17 ± 1.09 43.98 ± 1.68 
MCV (fl) 55.04 ± 2.94 54.38 ± 2.27 54.39 ± 1.96 55.54 ± 1.34 
MCH (pg) 19.80 ± 0.88 19.64 ± 0.71 19.65 ± 0.67 19.76 ± 0.48 
MCHC (g/dl) 36.00 ± 0.40 36.11 ± 0.48 36.11 ± 0.26 35.56 ± 0.57 
Platelet (103 1152.7  µl) ± 127.6 1212.2 ± 109.4 1186.4 ± 121.6 1186.6 ± 118.2 
Neutrophil (%) 17.99 ± 4.95 16.24 ± 3.82 14.07 ± 2.98 18.90 ± 5.31 
Lymphocyte (%) 78.02 ± 4.69 79.31 ± 4.03 81.68 ± 3.02 76.95 ± 5.72 
Monocyte (%) 3.74 ± 0.82 4.25 ± 0.75 4.04 ± 0.45 3.94 ± 1.07 
Eosinophil (%) 0.18 ± 0.12 0.12 ± 0.09 0.14 ± 0.08 0.15 ± 0.14 
Basophil (%) 0.07 ± 0.05 0.08 ± 0.06 0.07 ± 0.05 0.06 ± 0.05 
PT (sec) 12.84 ± 1.27 12.94 ± 0.83 13.37 ± 1.31 12.67 ± 2.13 
APTT (sec) 17.33 ± 1.36 17.42 ± 0.77 17.36 ± 1.20 17.26 ± 1.49 
Female             
WBC (103 6.832  µl) ± 1.828 5.831 ± 1.295 5.931 ± 2.502 7.517 ± 2.335 
RBC (106 7.654  µl) ± 0.340 7.575 ± 0.314 7.743 ± 0.264 7.612 ± 0.283 
HGB (g/dl) 15.16 ± 0.44 15.10 ± 0.61 15.26 ± 0.52 15.08 ± 0.57 
HCT (%) 41.03 ± 0.89 40.78 ± 1.74 41.47 ± 1.33 40.93 ± 1.14 
MCV (fl) 53.64 ± 1.81 53.89 ± 2.23 53.59 ± 2.00 53.81 ± 1.38 
MCH (pg) 19.82 ± 0.46 19.96 ± 0.74 19.71 ± 0.71 19.81 ± 0.61 
MCHC (g/dl) 36.94 ± 0.45 37.04 ± 0.50 36.80 ± 0.32 36.83 ± 0.59 
Platelet (103 1070.2  µl) ± 161.3 1068.2 ± 40.3 1067.7 ± 112.0 1106.3 ± 150.5 
Neutrophil (%) 13.18 ± 4.61 14.86 ± 3.27 12.29 ± 1.66 15.99 ± 10.15 
Lymphocyte (%) 83.94 ± 5.16 82.34 ± 3.51 85.05 ± 2.00 81.15 ± 10.39 
Monocyte (%) 2.53 ± 0.89 2.58 ± 0.69 2.34 ± 0.76 2.37 ± 0.46 
Eosinophil (%) 0.30 ± 0.14 0.21 ± 0.14 0.24 ± 0.12 0.43 ± 0.18 
Basophil (%) 0.05 ± 0.08 0.01 ± 0.03 0.08 ± 0.10 0.06 ± 0.07 
PT (sec) 9.54 ± 0.28 9.43 ± 0.15 9.30 ± 0.15 9.65 ± 0.35 
APTT (sec) 14.37 ± 0.88 14.55 ± 1.27 14.19 ± 0.47 14.27 ± 0.92 
Data were expressed as mean±SD (n=10), White blood cell (WBC), red blood cell (RBC), haemoglobin (HGB), haematocrit (HCT), mean corpuscular 
volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), prothrombin time (PT) and activated 
partial thromboplastin time (APTT). 
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Table 7: Effects of L. nuda mycelia on serum biochemistry parameters in male and female S-D rats during the 4-w safety assessment 
Parameters Control (Distilled water) L. nuda mycelia (g/kg/d) 
1 g/kg/d 2 g/kg/d 3 g/kg/d 
Male     
AST (U/l) 123.55 ± 19.28 105.81 ± 18.19 97.97 ± 14.20 109.34 * ± 22 
ALT (U/l) 30.88 ± 8.64 30.93 ± 5.29 29.26 ± 3.27 33.03 ± 5.90 
GLU (mg/dl) 168.86 ± 32.94 150.62 ± 13.01 165.71 ± 18.38 160.12 ± 28.84 
TP (g/dl) 5.56 ± 0.18 5.82 ± 0.15* 5.64 ± 0.20 5.62 ± 0.21 
Albumin (g/dl) 4.09 ± 0.11 4.22 ± 0.11 4.16 ± 0.13 4.07 ± 0.22 
T-BIL (mg/dl) <0.05 <0.04 <0.06 <0.04 
BUN (mg/dl) 12.58 ± 1.95 13.35 ± 1.77 12.10 ± 1.52 11.62 ± 1.15 
CRE (mg/dl) 0.32 ± 0.04 0.34 ± 0.05 0.31 ± 0.03 0.32 ± 0.04 
γ-GT (U/l) <2.0 <2.0 <2.0 <2.0 
ALP (U/l) 512.85 ± 87.17 607.07 ± 125.80 615.63 ± 91.05 668.93 ± 163.19* 
CHO (mg/dl) 50.07 ± 7.59 51.04 ± 7.54 46.30 ± 6.68 46.72 ± 12.80 
TG (mg/dl) 33.11 ± 9.71 26.83. ± 6.93 29.46 ± 9.11 26.60 ± 10.04 
Ca (mg/dl) 9.91 ± 0.24 9.99 ± 0.30 10.12 ± 0.14 9.81 ± 0.20 
P (mg/dl) 8.09 ± 0.23 8.39 ± 0.41 8.34 ± 0.37 8.48 ± 0.37
CK (U/l) 
* 
676.26 ± 301.71 547.51 ± 244.85 461.83 ± 181.23 498.95 ± 238.96 
Amylase (U/l) 1328.6 ± 222.0 1388.9 ± 202.6 1345.2 ± 188.8 1269.9 ± 243.5 
Na (mmol/l) 146.17 ± 1.53 147.89 ± 1.38 148.49 * ± 0.71 149.25 * ± 1.23
K (mmol/l) 
* 
4.118 ± 0.303 4.180 ± 0.216 4.205 ± 0.144 4.206 ± 0.200 
Cl (mmol/l) 106.68 ± 1.46 109.03 ± 1.25 109.93 * ± 1.54 109.66 * ± 1.80
Female 
* 
            
AST (U/l) 68.22 ± 10.17 78.05 ± 11.62 72.60 ± 9.12 67.82 ± 10.96 
ALT (U/l) 21.89 ± 2.83 23.43 ± 4.05 22.70 ± 2.14 20.99 ± 2.59 
GLU (mg/dl) 157.31 ± 33.17 158.97 ± 24.36 157.42 ± 27.26 154.42 ± 27.59 
TP (g/dl) 5.58 ± 0.21 5.76 ± 0.33 5.46 ± 0.30 5.63 ± 0.26 
Albumin (g/dl) 4.30 ± 0.18 4.43 ± 0.29 4.19 ± 0.34 4.33 ± 0.28 
T-BIL(mg/dl) <0.04 <0.04 <0.05 <0.04 
BUN (mg/dl) 13.91 ± 1.00 14.10 ± 2.55 13.76 ± 1.67 12.81 ± 1.62 
CRE (mg/dl) 0.32 ± 0.04 0.36 ± 0.05 0.34 ± 0.05 0.32 ± 0.06 
γ-GT (U/l) <2.0 <2.0 <2.0 <2.0 
ALP (U/l) 340.48 ± 96.47 351.38 ± 89.08 321.68 ± 61.10 345.88 ± 81.68 
CHO (mg/dl) 65.72 ± 17.87 63.43 ± 12.52 69.48 ± 12.38 59.13 ± 7.40 
TG (mg/dl) 19.89 ± 5.70 19.08 ± 8.04 21.73 ± 8.88 22.15 ± 8.41 
Ca (mg/dl) 9.77 ± 0.24 9.93 ± 0.25 9.77 ± 0.18 10.00 ± 0.29 
P (mg/dl) 6.92 ± 0.65 6.78 ± 0.72 6.86 ± 0.50 7.12 ± 0.69 
CK (U/l) 162.93 ± 54.08 274.58 ± 153.56* 241.08 ± 79.15 191.40 ± 87.57 
Amylase (U/l) 716.1 ± 90.7 841.9 ± 285.4 812.3 ± 171.3 755.3 ± 122.4 
Na (mmol/l) 144.13 ± 1.36 143.88 ± 1.27 143.67 ± 1.02 144.46 ± 1.80 
K (mmol/l) 3.796 ± 0.163 3.987 ± 0.240 3.922 ± 0.406 4.013 ± 0.333 
Cl (mmol/l) 109.67 ± 1.32 109.60 ± 1.67 108.57 ± 1.70 109.28 ± 1.63 
Data were expressed as mean±SD (n=10), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose (GLU), total protein (TP), 
total bilirubin (T-BIL), blood urea nitrogen (BUN), creatinine (CRE), gamma-glutamyltransferase (γ-GT), alkaline phosphatase (ALP), cholesterol 
(CHO), triglycerides (TG), calcium (Ca), phosphorus (P), creatine kinase (CK), sodium (Na), potassium (K), and chloride (Cl), * Statistically significant 
(p<0.05) when compared to the control group. 
 
There were no abnormal urinalysis (table 8) and no abnormal relative 
organ weight findings (table 9) in any of the L. nuda mycelia treated 
groups when compared to either sex of the control group. Upon 
histopathological examination of the control and high dose groups, no 
treatment-related toxicological significances were observed (data not 
shown). Summing up the results, the NOAEL (no-observable-adverse-
effect-level) of L. nuda mycelia is 3 g/kg/d, which could be used as a 
reference for possible exposure levels of its consumption. 
 
Table 8: Urinalysis values of male and female SD rats with L. nuda mycelia for 4 w 
Parameters Control (Distill water) L. nuda mycelia (g/kg/d) 
1 g/kg/d 2 g/kg/d 3 g/kg/d 
Male     
Volume (ml) 15.05 ± 7.32 14.40 ± 6.43 22.00 ± 11.03 21.15 ± 4.16 
Specific Gravity 1.0170 ± 0.0059 1.0135 ± 0.0041 1.0178 ± 0.0051 1.0170 ± 0.0026 
pH 7.00 ± 0.00 7.00 ± 0.00 6.90 ± 0.21 6.95 ± 0.16 
Urobilinogen (EU/dl) 0.20 ± 0.00 0.20 ± 0.00 0.20 ± 0.00 0.20 ± 0.00 
Female             
Volume (ml) 15.05 ± 7.32 14.40 ± 6.43 14.40 ± 7.86 16.40 ± 6.89 
Specific Gravity 1.0150 ± 0.0041 1.0165 ± 0.0041 1.0170 ± 0.0035 1.0144 ± 0.0017 
pH 7.05 ± 0.16 7.10 ± 0.21 7.25 ± 0.54 6.95 ± 0.16 
Urobilinogen (EU/dl) 0.20 ± 0.00 0.20 ± 0.00 0.20 ± 0.00 0.20 ± 0.00 
Data were expressed as mean±SD (n=10) 
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Table 9: Effects of L. nuda mycelia on relative organ weight of male and female SD rats during the 4-w safety assessment 
Relative weight (%) Control (Distilled water) L. nuda mycelia (g/kg/d) 
1 g/kg/d 2  g/kg/d 3  g/kg/d 
Male     
Adrenal gland (Paired) 0.05597 ± 0.00540 0.05664 ± 0.00701 0.05901 ± 0.00735 0.05663 ± 0.00594 
Thymus  0.656 ± 0.091 0.566 ± 0.115 0.577 ± 0.118 0.625 ± 0.095 
Heart  1.268 ± 0.092 1.239 ± 0.091 1.203 ± 0.107 1.243 ± 0.093 
Kidney (Paired) 3.048 ± 0.219 3.054 ± 0.290 3.028 ± 0.261 3.053 ± 0.289 
Liver  11.738 ± 0.956 11.774 ± 0.762 11.031 ± 1.171 11.670 ± 1.213 
Spleen  0.714 ± 0.119 0.716 ± 0.141 0.708 ± 0.072 0.721 ± 0.091 
Testis (Paired) 3.166 ± 0.184 3.180 ± 0.417 3.236 ± 0.296 3.184 ± 0.241 
Epididymis (Paired) 0.929 ± 0.095 0.937 ± 0.127 0.946 ± 0.102 0.937 ± 0.056 
Female             
Adrenal gland (Paired) 0.06602 ± 0.01083 0.07203 ± 0.00993 0.06669 ± 0.01039 0.06986 ± 0.01560 
Ovary and fallopian tube 0.13446 ± 0.02095 0.14608 ± 0.02262 0.13085 ± 0.02296 0.13506 ± 0.02151 
Heart  0.857 ± 0.070 0.879 ± 0.092 0.833 ± 0.062 0.866 ± 0.070 
Kidney (Paired) 1.787 ± 0.103 1.881 ± 0.225 1.808 ± 0.214 1.909 ± 0.215 
Liver  7.229 ± 0.629 7.510 ± 0.920 7.098 ± 0.838 7.461 ± 0.988 
Uterus and cervical  0.540 ± 0.293 0.443 ± 0.136 0.409 ± 0.097 0.393 ± 0.100 
Thymus  0.545 ± 0.067 0.538 ± 0.113 0.469 ± 0.077 0.498 ± 0.065 
Spleen  0.555 ± 0.075 0.535 ± 0.085 0.487 ± 0.072 0.538 ± 0.086 
Data were expressed as mean±SD (n=10). 
 
CONCLUSION 
In summary, no mutagenic effects and no evidence of systemic 
toxicity were found in this safety assessment, which suggest that the 
use of L. nuda mycelia is safe at a dose of 3 g/kg body weight in S-D 
rats. Using a safety factor of 100, the calculated acceptable daily 
intake in humans is 30 mg/kg body weight/d. Additional research 
on L. nuda mycelia, including a longer term animal study and a year-
long human clinical trial, is suggested to further support the safety of 
its consumption. 
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